Veradigm 8K This communication contains forward-looking statements within the meaning of the federal securities | MDRX 13 Jan 10

Allscripts

Investor

Presentation

–

January,

2010

EXHIBIT 99.1

Forward Looking Statements

This communication contains forward-looking statements within the meaning of the federal securities

laws. Statements regarding future events, developments, the Company’s future performance, as

well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the

future are forward-looking statements within the meaning of these laws. These forward-looking

statements are subject to a number of risks and uncertainties, some of which are outlined below. As

a result, actual results may vary materially from those anticipated by the forward-looking statements.

Among the important factors that could cause actual results to differ materially from those indicated

by such forward-looking statements are: the volume and timing of systems sales and installations;

length of sales cycles and the installation process; the possibility that products will not achieve or

sustain market acceptance; the timing, cost and success or failure of new product and service

introductions, development and product upgrade releases; competitive pressures including product

offerings, pricing and promotional activities; our ability to establish and maintain strategic

relationships; undetected errors or similar problems in our software products; compliance with

existing laws, regulations and industry initiatives and future changes in laws or regulations in the

healthcare industry; possible regulation of the Company’s software by the U.S. Food and Drug

Administration; the possibility of product-related liabilities; our ability to attract and retain qualified

personnel; our ability to identify and complete acquisitions, manage our growth and integrate

acquisitions; the ability to recognize the benefits of the merger with Misys Healthcare Systems, LLC

(“MHS”); the integration of MHS with the Company; the impact of the securities class action and

other pending or threatened litigation and the possible disruption of current plans and operations as a

result thereof; the implementation and speed of acceptance of the electronic record provisions of the

American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and

litigation

involving

intellectual

property

rights;

risks

third-party

suppliers;

our

ability

obtain, use or successfully integrate third-party licensed technology; breach of our security by third

parties; and the risk factors detailed from time to time in our reports filed with the Securities and

Exchange Commission, including our most recent Annual Report on Form 10-K available through the

Web

site

maintained

the

Securities

and

Exchange

Commission

www.sec.gov.

The

Company

undertakes no obligation to update publicly any forward-looking statement, whether as a result of

new information, future events or otherwise.

Agenda

›

Market Opportunity is Now

›

Meaningful Use Update

›

Why Allscripts?

›

Financial Update

We are at the beginning of the

single fastest transformation

of any industry in US history

2010: The Year of the EHR

<20

Approx. 20% EHR

Penetration

-Early Adopters

$48B

~$48 Billion in

Federal Funding

70% of funding will be

spent

in first 3 years

Lower IT Investment in Healthcare Than Any Other Sector of Economy

Market Potential

Practice Size

Total # of Practices

EHR Penetration

(FY08/09)

1-3 Physicians

163,000

~10%

4-9 Physician

27,000

~20%

10-25 Physicians

8,000

~25%

26+ Physicians

2,000

~40%

Total

200,000

~12%

Source: SK&A = SK&A

Information Services which sells databases for sales and marketing success in healthcare industry

Once in a Lifetime Opportunity…

Meaningful Use Update: The Time is Now

Health

care

reform

will

not

impact

ARRA

~$40B

for

EHRs

›

Medicare

$44,000;

Medicaid

$63,750

›

Rules issued December 30, 2009

›

Notice of Proposed Rule Making (NPRM)

how physicians earn incentives

60 day comment period ends March 15

›

Interim Final Rule (IFRM)

how products get certification

no surprises

›

Penalties for not participating

Meaningful Use Update: Key Components

›

The EHR must be certified

& include e-prescribing

›

The EHR must be connected

›

The EHR must include reporting capabilities on clinical

quality metrics

›

The EHR must be used in a meaningful way

Why Allscripts?

›

Leadership

The clear leader in providing innovative software, connectivity and

information solutions that empower physicians and other healthcare

providers

improve

the

health

both

their

patients

and

their

bottom

line

›

A Safe Choice

Financially Strong

Revenue of ~ $700mm

R&D 2010 ~$70 million

›

People & Experience

Our Footprint…

160,000 Physicians

8,000 Post-Acute Providers

800 Hospitals

and 80 million Rx…

Comprehensive Portfolio…

Across the Continuum of Care

Connect

Powerful Engine to Drive Sales

Hospital/Community Distribution Partners

Henry Schein; Cardinal Health

Allscripts

Distribution Network

Direct Marketing

~250 Direct Sales Professionals

Summary

›

Unparalled

Market Opportunity

›

Rapid Transformation

›

“Rules of the Road”

for Capturing Stimulus in Place

›

Allscripts

“Built to Last”

Financial Overview

Allscripts

–

Financial Highlights

›

$191.3 million in H1 bookings –

30% growth

›

$680.0 million run rate revenue

›

Visibility –

67% Recurring Revenue

›

mix of SaaS

Bookings

›

Improving Gross Margins

›

Significant Operating Leverage

›

Substantial R&D Expenditures ~ $70.0 million or ~10% of

Revenue in Fiscal 2010

›

Strong Financial Position

Fiscal 2010 2Q & YTD Bookings Results

Quarter Ended

11/30/08

11/30/09

% Change

Bookings

$80.7

$93.8

16%

% SaaS

26%

24%

Six Months Ended

11/30/08

11/30/09

% Change

Bookings

$147.1

$191.3

30%

% SaaS

24%

25%

Strong 2Q and YTD bookings across all of our product offerings

Fiscal 2010 2Q Revenue and Net Income

Q2 ‘09

Q2 ‘10

% Change

Revenue

$128.6

$169.3

32%

Non-GAAP Revenue(a)

$163.4

$170.7

% Recurring Revenue

63%

67%

Net Income

($6.0)

$15.8

N/M

Non-GAAP Net Income(a)

$16.6

$24.0

45%

(a) Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP revenue

and net income for the three months ended November 30, 2009 and 2008. Information also available at

http://investor.allscripts.com

Gross Profit Margin Improvements

54.0%

56.4%

54.7%

56.8%

40.0%

45.0%

50.0%

55.0%

60.0%

Non-GAAP(a)

GAAP

(a) Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP gross

profit margin for the three months ended August 31, 2009 and November 30, 2009. Information also

available at http://investor.allscripts.com

Operating Income Growth -

Fiscal 2010

$21.6

$26.7

$37.2

$39.7

$15.0

$25.0

$35.0

$45.0

Non-GAAP(a)

GAAP

(a) Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP operating

profit for the three months ended November 30, 2009. Additional information also available at

http://investor.allscripts.com

Fiscal 2010 Outlook

2010E

Revenue

(2009 non-GAAP)

$680.0 -

$700.0

Net income

$64.5 -

$66.0

Non-GAAP net

income(a)

$93.5 -

$95.0

Diluted EPS

$0.41 -

$0.43

Non-GAAP

diluted EPS(a)

$0.61 -

$0.63

WASO

150.5

(a)

Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP revenue, net

income and EPS for the year ended May 31, 2009 and 2010. Information also available at

http://investor.allscripts.com

›

~10% Top Line Growth

›

Mid 50’s Gross Margin %

›

Significant Operating

Leverage

›

Non-GAAP Net Income

Growth 22-24%

›

Strong Operating Cash

Flow

Appendix: Non-GAAP Reconciliation

›

GAAP –

non-GAAP revenue reconciliation for the three months ended November 30, 2008 and

2009.

2009

2010

Nov-08

Nov-09

Revenue

Revenue, as reported

$128.6

$169.3

Allscripts

pre-merger

37.4

Deferred revenue adjustment

2.1

1.4

Elimination of prepackaged medications

(4.7)

Revenue, non-GAAP

$163.4

$170.7

Appendix: Non-GAAP Reconciliation

›

GAAP

–

non-GAAP

net

income

reconciliation

for

the

three

months

ended

November

30,

2008

and

2009.

2009

2010

Nov-08

Nov-09

Net income

Net income, as reported

$ (6.0)

$ 15.8

Allscripts

pre-merger

7.9

Elimination of prepackaged medications

(0.3)

Deferred revenue adjustment

2.0

1.5

Stock based compensation

1.0

4.4

Acquisition-related amortization expense

4.6

5.7

Transaction-related expense

22.0

1.3

Tax effect of non-GAAP adjustments (at 39%)

(14.6)

(5.0)

Tax adjustment to bring as-reported to 39%

0.3

Net income, non-GAAP

$16.6

$24.0

Appendix: Non-GAAP Reconciliation

›

GAAP –

non-GAAP gross profit margin reconciliation for the three months ended August 31, 2009

and November 30, 2009.

2010

Aug-09

Nov-09

Gross margin

Gross margins, as reported

$89.1

$95.5

% of revenue

54.0%

56.4%

Deferred revenue adjustment

2.6

1.4

Gross margins, non-GAAP

$91.7

$96.9

% of non-GAAP revenue

54.7%

56.8%

Appendix: Non-GAAP Reconciliation

›

GAAP –

non-GAAP operating income reconciliation for the three months ended August 31, 2009

and November 30, 2009

2010

Aug-09

Nov-09

Operating income

Operating income as reported

$21.6

$26.7

Deferred revenue adjustment

2.6

1.5

Stock based compensation

3.3

4.4

Amortization of intangibles

5.7

Transaction-related expense

3.9

1.3

Operating income, non-GAAP

$37.1

$39.6

Appendix: Non-GAAP Reconciliation

›

GAAP –

non-GAAP Net Income and EPS reconciliation for the year ended May 31, 2009 and 2010

Fiscal 2009

Fiscal 2010

Guidance

Guidance Range

Net income

$26.0

$65.3

$64.5 to $66.0

GAAP EPS

$0.21

$0.43

$0.41 to $0.43

Adjustments*

Allscripts

pre-merger

11.4

Elimination of prepackaged

medications

(2.4)

Deferred revenue adjustment

7.8

4.9

Stock based compensation

8.3

15.2

Acquisition-related amortization

expense

20.5

22.6

Transaction-related expense

40.3

5.2

Tax effect of non-GAAP

adjustments (41% in 2009 and

39% in 2010)

(35.2)

(18.6)

Non-GAAP Net income

$76.7

$94.6

$93.5 to $95.0

Share count

149.9

150.5

Non-GAAP EPS

$0.51

$0.63

$.61 to $.63

Appendix: Non-GAAP Reconciliation

Fiscal

2009

Revenue

Revenue, as reported

$548.4

Allscripts

pre-merger

124.3

Deferred revenue adjustment

7.8

Elimination of prepackaged medications

(29.6)

Revenue, non-GAAP

$650.9

›

GAAP

–

non-GAAP

revenue

reconciliation

for

the

year

ended

May

31,

2009.

Basis of Presentation

The Company's GAAP results for the three and six months ended November 30, 2009 include results of Allscripts for each such period. The Company's

GAAP results for the three and six months ended November 30, 2008 include the results of Misys Healthcare (Misys) for each period and the results of

Allscripts subsequent to a merger effected on October 10, 2008, at which time the Company's legal name was changed to Allscripts-Misys Healthcare

Solutions, Inc.

Footnotes

1. Non-GAAP revenue for the three months ended November 30, 2009 and 2008, respectively, are comprised of revenue from Allscripts and Misys for the full three

month period of each respective year, giving effect to the add-back of a deferred revenue adjustment of $1.4 million recorded for GAAP purposes in the three

month period ended November 30, 2009 and $2.1 million for the same period last year. In addition, non-GAAP revenue for the three months ended

November 30, 2008 excludes $4.7 million in prepackaged medications revenue that were recorded for GAAP purposes. Allscripts disposed of its

prepackaged medications business on March 16, 2009. Non-GAAP revenue for the six months ended November 30, 2009 and 2008, respectively, are

comprised of revenue from Allscripts and Misys for the full six month period of each respective year, giving effect to the add-back of a deferred revenue

adjustment of $4.0 million recorded for GAAP purposes in the six month period ended November 30, 2009 and $2.1 million for the same period last year. In

addition, non-GAAP revenue for the six months ended November 30, 2008 excludes $4.7 million in prepackaged medications revenue that were recorded for

GAAP purposes.

2. Non-GAAP gross margin for the three months ended November 30, 2009 and 2008, respectively, are comprised of gross profit from Allscripts and Misys for the

full three month period of each respective year, giving effect to the add-back of a deferred revenue adjustment of $1.4 million recorded for GAAP purposes in

the three month period ended November 30, 2009 and $2.1 million for the same period last year. In addition, non-GAAP gross margin for the three months

ended November 30, 2008 excludes $0.8 million in prepackaged medications gross profit that were recorded for GAAP purposes. Non-GAAP gross margin

for the six months ended November 30, 2009 and 2008, respectively, are comprised of gross profit from Allscripts and Misys for the full six month period of

each respective year, giving effect to the add-back of a deferred revenue adjustment of $4.0 million recorded for GAAP purposes in the six month period

ended November 30, 2009 and $2.1 million for the same period last year. In addition, non-GAAP gross margin for six months ended November 30, 2008

excludes $0.8 million in prepackaged medications gross profit that were recorded for GAAP purposes.

3. Non-GAAP net income for the three months ended November 30, 2009 and 2008, respectively, are comprised of net income from Allscripts and Misys for the full

three month period of each respective year, giving effect to the add-back of acquisition-related amortization of $3.5 million and $2.8 million, respectively, net

of tax; stock-based compensation expense of $2.7 million and $0.6 million, respectively, net of tax; transaction-related expenses of $0.8 million and $13.4

million, respectively, net of tax; and a deferred revenue adjustment of $0.9 million and $1.2 million, respectively, net of tax. Non-GAAP net income also

eliminates prepackaged medications net income of $0.2 million, net of tax, for the three months ended November 30, 2008 and adds-back a tax adjustment

of $0.3 million for the three months ended November 30, 2009. Non-GAAP net income for the six months ended November 30, 2009 and 2008, respectively,

are comprised of net income from Allscripts and Misys for the full six month period of each respective year, giving effect to the add-back of acquisition-related

amortization of $6.9 million and $5.2 million, respectively, net of tax; stock-based compensation expense of $4.7 million and $2.1 million, respectively, net of

tax; transaction-related expenses of $3.2 million and $17.6 million, respectively, net of tax; and a deferred revenue adjustment of $2.5 million and $1.2

million, respectively, net of tax. Non-GAAP net income also eliminates prepackaged medications net income of $0.7 million, net of tax, for the six months

ended November 30, 2008 and adds-back a tax adjustment of $0.1 million for the six months ended November 30, 2009.

4.Non-GAAP adjustments are effected for tax at the actual as-reported effective tax rate for all fiscal 2009 periods presented. Non-GAAP adjustments are effected

for tax at the anticipated full-year effective tax rate for all fiscal 2010 periods presented.

5. Please see next page for a further discussion of non-GAAP measures.

Supplemental

and

non-GAAP

financial

information

also

available

http://investor.allscripts.com.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this

presentation non-GAAP revenue, gross profit operating income and net income, including non-GAAP net income on a per share basis, which are non-GAAP financial measures

under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Non-GAAP revenue consists of GAAP revenue and legacy Allscripts revenue for

periods prior to the consummation date of the Misys merger and adds back the deferred revenue adjustment booked for GAAP purposes and excludes revenue from prepackaged

medications. Non-GAAP gross profit consists of GAAP gross profit and legacy Allscripts gross profit for periods prior to the consummation date of the Misys Healthcare merger

and adds back the deferred revenue adjustment booked for GAAP purposes and excludes revenue from prepackaged medications. Non-GAAP net income consists of GAAP net

income and includes legacy Allscripts net income for periods prior to the consummation date of the Misys merger, excludes acquisition-related amortization, stock-based

compensation expense and transaction-related expenses, adds back the deferred revenue adjustment and excludes net income from prepackaged medications, in each case net of

any related tax benefit.

Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with acquisitions

or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP net income because it believes (i) the amount of such expenses in any specific period

may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of new

acquisitions and full amortization of previously acquired intangible assets. Management believes that this adjustment facilitates comparisons of the separate pre-merger results of

legacy Misys and legacy Allscripts to that of the Company's post-merger results. Investors should note that the use of these intangible assets contributed to revenue in the periods

presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock awards to employees. Allscripts excludes stock-

based compensation expense from non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying

performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards,

including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the

operating results in the periods presented and are expected to contribute to operating results in future periods and should also note that such expense will recur in future periods.

Deferred Revenue Adjustment. Deferred revenue adjustment reflects the fair value adjustment to deferred revenues acquired in connection with the Misys merger transaction

consummated on October 10, 2008. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services

related to legacy Allscripts software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of October 10, 2008. Allscripts

adds back this deferred revenue adjustment for non-GAAP revenue and non-GAAP net income because it believes the inclusion of this amount directly correlates to the underlying

performance of Allscripts operations and facilitates comparisons of the separate pre-merger results of legacy Misys and legacy Allscripts to that of the Company's post-merger

results.

Management also believes that non-GAAP revenue, gross profit and net income provide useful supplemental information to management and investors regarding the underlying

performance of the Company's business operations and facilitates comparisons of the separate pre-merger results of legacy Misys and legacy Allscripts to that of the Company's

post-merger results. Purchase accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the

business without considering the non-GAAP adjustments that we have provided and discussed herein. Management also uses this information internally for forecasting and

budgeting as it believes that the measure is indicative of the Company's core operating results. In addition, the Company uses Non-GAAP net income to measure achievement

under the Company's cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit and net income are performance measures only, and they do not

provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance

prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all

of the amounts associated with Allscripts' results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the

reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

Veradigm (MDRX) 8-KThis communication contains forward-looking statements within the meaning of the federal securities